Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company and Acrux have got the US Food and Drug Administration (FDA) approval for Axiron (testosterone) topical solution CIII for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
Subscribe to our email newsletter
Eli Lilly and Acrux claim that Axiron is the first testosterone topical solution approved for application via an armpit (underarm) applicator.
Lilly USA president David Ricks said that the addition of Axiron to the product portfolio reinforces Lilly’s commitment to provide innovative treatment options for patients.
Acrux CEO Richard Treagus said that the FDA approval is a major milestone for Axiron and for Acrux.
"After years of research, we are excited to partner with Lilly to provide this novel application method for men with low testosterone," Treagus said.